STOCK TITAN
  1. Home
  2. News
  3. AWH

Aspira Women's Health Inc. - AWH STOCK NEWS

Welcome to our dedicated page for Aspira Women's Health news (Ticker: AWH), a resource for investors and traders seeking the latest updates and insights on Aspira Women's Health stock.

Aspira Women's Health Inc. (Nasdaq: AWH) is a pioneering company focused on the development and commercialization of noninvasive diagnostic tests for gynecologic diseases. The company is at the forefront of women's health, offering innovative solutions that leverage bio-analytical techniques and artificial intelligence.

One of Aspira's flagship products is OvaSuite, a comprehensive portfolio of blood tests designed to assess the risk of ovarian cancer. This suite includes the well-known OvaWatch and Ova1Plus tests. OvaWatch, with a negative predictive value of 99%, is instrumental in evaluating ovarian cancer risk in women with adnexal masses that appear indeterminate or benign, potentially allowing them to avoid unnecessary surgeries. Ova1Plus combines two FDA-cleared tests, Ova1® and Overa®, providing a robust assessment for women scheduled for surgery due to pelvic masses.

In addition to ovarian cancer diagnostics, Aspira is expanding its test pipeline to address other pressing women's health issues. The company is developing EndoCheck, the first-ever noninvasive test for identifying endometriomas, a common form of endometriosis. Another promising test in development is OvaMDx, which combines microRNA and protein biomarkers with patient data to enhance the accuracy of ovarian cancer risk assessments.

The company's commitment to innovation is reflected in its recent achievements. Aspira has published significant clinical studies demonstrating the efficacy of OvaWatch in longitudinal monitoring of ovarian cancer risk, which could significantly reduce surgical backlogs and unnecessary referrals. Furthermore, Aspira has made strides in market access, securing payer coverage from Anthem Blue Cross and expanding its reach to millions of lives across various health plans.

Financially, Aspira has shown remarkable progress. In 2023, the company significantly reduced its operational cash use while increasing revenues and test volumes. These accomplishments were accompanied by important enhancements to their commercial organization and the achievement of key market access milestones. As of December 31, 2023, Aspira had $2.9 million in cash and raised an additional $5.5 million through a registered direct offering and private placement.

The management team, led by CEO Nicole Sandford, has positioned Aspira for substantial growth in 2024 and beyond. The company's forward-looking strategies and robust test pipeline are set to meet the growing demand for noninvasive diagnostics in women's health, offering new hope and improved outcomes for millions of women worldwide.

News

Aspira Women’s Health to Present at The Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference

Rhea-AI Summary
Aspira Women’s Health Inc. announces participation in The Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference. The Company will present a corporate overview and be available for one-on-one meetings with investors. Date: March 1, 2024, Time: 9:30 am CST / 10:30 am EST.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.36%
Tags
conferences
-
News

Aspira Women’s Health Announces Late-Breaking Poster Presentation at the Upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI)

Rhea-AI Summary
Aspira Women’s Health Inc. announces a late-breaking poster presentation at the 71st Annual Scientific Meeting for the Society for Reproductive Investigation. The presentation focuses on EndoCheckSM, a noninvasive diagnostic test for endometriosis, a common gynecologic disease affecting millions of women. The poster details a Protein Biomarker Test and Artificial Intelligence-Based Algorithm for Ovarian Endometriosis, co-authored by Aspira’s R&D team and the Oxford Endometriosis Care and Research Centre. The presentation is a significant step towards launching a groundbreaking diagnostic tool for this debilitating disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
none
-
News

Aspira Women’s Health Announces OvaSuite(SM) Distribution Agreement in the Philippines

Rhea-AI Summary
Aspira Women’s Health Inc. signs a 5-year distribution agreement with Hi-Precision Laboratories, the largest medical laboratory in the Philippines, to market and distribute the OvaSuite portfolio in the country. The agreement includes royalties to Aspira for each test performed. This partnership aims to improve the detection of early-stage ovarian cancer in Filipino women, addressing the higher risk of ovarian cancer in the Philippines compared to other parts of the world.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.58%
Tags
none
News

Aspira Women’s Health Announces $5.5 Million Registered Direct Offering and Concurrent Private Placement

Rhea-AI Summary
Aspira Women’s Health Inc. announced a registered direct offering and concurrent private placement of 1,571,000 shares of its common stock at a combined purchase price of $3.50 per share to institutional investors and existing shareholders. CEO Nicole Sandford and certain existing shareholders will also participate in the purchase. The warrants will have exercise prices ranging from $4.00 to $4.13 per share, with expiration 5 years from the initial exercise date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.87%
Tags
offering
-
News

Aspira Women’s Health to Host R&D Day With Updates on the Development of the Company's Ovarian Cancer and Endometriosis Tests on January 4, 2024

Rhea-AI Summary
Aspira Women’s Health Inc. (Nasdaq: AWH) to host virtual R&D day on January 4, 2024, featuring updates on the development of ovarian cancer and endometriosis tests. The event will showcase progress in the company’s product pipeline, including OvaWatch, OvaMDx, EndoCheck, and EndoMDx.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
conferences
-
News

Aspira Women’s Health to Participate in Corporate Access Events During JP Morgan Healthcare Conference Week 2024

Rhea-AI Summary
Aspira Women’s Health Inc. (AWH) will be available for meetings in San Francisco from January 8-10, 2024, during JP Morgan’s Healthcare Conference Week. Nicole Sandford, President and CEO, and Torsten Hombeck, CFO, will be attending the 12th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright & Co. Hosted Investor Meetings for partnering and institutional one-on-one meetings. Aspira is a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.48%
Tags
conferences
News

Aspira Women’s Health Provides a Development Update on its Portfolio of Noninvasive Tests for Endometriosis

Rhea-AI Summary
Aspira Women’s Health Inc. (Nasdaq: AWH) has developed EndoCheck, the first blood test for identifying localized endometriosis, including endometrioma, with plans for a commercial launch in 2024. The test is expected to offer a non-invasive alternative to laparoscopic surgery for endometriomas, potentially addressing a market of up to 2.5 million women in the U.S. The company is also working on the development of EndoMDx, a broader test for all types and locations of endometriosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.69%
Tags
none
-
News

Aspira Women’s Health Secures Reimbursement for Ova1Plus(R) from California Medicaid (Medi-Cal)

Rhea-AI Summary
Aspira Women’s Health Inc. (AWH) announced that California Medicaid (Medi-Cal) added Ova1Plus® to its fee schedule at $897 per test. Aspira will be reimbursed at a rate of $897 for all Ova1Plus® tests processed for Medi-Cal patients meeting applicable coverage requirements, effective from October 15, 2023. The addition of Ova1Plus® to the fee schedule provides expanded access to this groundbreaking technology for women in California facing an ovarian cancer diagnosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.6%
Tags
none
-
News

Aspira Women’s Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS)

Rhea-AI Summary
Aspira Women’s Health Inc. (AWH) receives CMS approval for OvaWatch 2024 price at $897 per test. The Centers for Medicare & Medicaid Services (CMS) has approved the reimbursement rate for OvaWatch and Ova1 tests processed for Medicare patients, beginning January 1, 2024. Aspira's President and CEO, Nicole Sandford, emphasizes the importance of reliable clinical data in ovarian cancer diagnosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
none
News

Aspira Women’s Health Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Aspira Women’s Health Inc. (Nasdaq: AWH) reported a 9% increase in product revenue to $2.2 million for the quarter and a 19% increase to $7.0 million year to date. OvaSuite sales volume increased 5% to 5,783 units for the quarter and 16% to 18,331 units year to date. The company also highlighted significant achievements in the development of new products and the establishment of a Clinical Advisory Board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.6%
Tags
earnings

FAQ

What is the current stock price of Aspira Women's Health (AWH)?

The current stock price of Aspira Women's Health (AWH) is $0.7401 as of November 14, 2024.

What is the market cap of Aspira Women's Health (AWH)?

The market cap of Aspira Women's Health (AWH) is approximately 12.4M.

What is Aspira Women's Health Inc. known for?

Aspira Women's Health Inc. is known for developing and commercializing noninvasive diagnostic tests for gynecologic diseases, particularly ovarian cancer.

What products does Aspira offer?

Aspira offers OvaSuite, which includes OvaWatch and Ova1Plus. These are blood tests designed to assess the risk of ovarian cancer in women with adnexal masses.

How effective is OvaWatch?

OvaWatch has a negative predictive value of 99%, making it highly effective in assessing ovarian cancer risk in women with indeterminate or benign adnexal masses.

What is Ova1Plus?

Ova1Plus is a combination of two FDA-cleared tests, Ova1® and Overa®, designed to assess the risk of ovarian malignancy in women planned for surgery.

What recent achievements has Aspira made?

Aspira has recently published significant clinical studies, secured Anthem Blue Cross payer coverage, and reduced operational cash use while increasing revenues and test volumes.

What is EndoCheck?

EndoCheck is the first-ever noninvasive test developed by Aspira to identify endometriomas, a common form of endometriosis.

How has Aspira performed financially recently?

In 2023, Aspira reduced its operational cash use, increased revenues, and achieved key market access milestones. They also raised $5.5 million through a direct offering and private placement.

Who leads Aspira Women's Health Inc.?

Aspira is led by CEO Nicole Sandford, who has guided the company through significant growth and innovation in women's health diagnostics.

What is OvaMDx?

OvaMDx is an in-development test that combines microRNA and protein biomarkers with patient data to enhance the sensitivity and specificity of ovarian cancer risk assessments.

How does Aspira's test pipeline address women's health issues?

Aspira's test pipeline, including EndoCheck and OvaMDx, aims to provide noninvasive diagnostic solutions for ovarian cancer and endometriosis, improving care and outcomes for millions of women.

Stock AWH logo
Aspira Women's Health Inc.

Nasdaq:AWH

AWH Rankings

#5472 Ranked by Market Cap
N/A Ranked by Dividends

AWH Stock Data

12.37M
16.06M
30.94%
8.62%
2.78%
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States of America
AUSTIN